AstraZeneca 2020 forecasts hit by coronavirus, shares dive

Shares of the company, moving into a third year of growth after changes driven by Chief Executive Officer Pascal Soriot, sank 5% on Britain’s blue-chip index as it warned that the hit from the outbreak could last “a few months”. China was again a central driver for the company in the final quarter of 2019, with sales in the country growing 28% to $1.19 billion, making up 19% of total product sales in the period. The 2020 forecast was broadly in line with expectations, although some analysts have said anything less than double-digit sales growth would be a …read more

Source:: Yahoo Finance

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.